JP2019506159A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019506159A5 JP2019506159A5 JP2018538551A JP2018538551A JP2019506159A5 JP 2019506159 A5 JP2019506159 A5 JP 2019506159A5 JP 2018538551 A JP2018538551 A JP 2018538551A JP 2018538551 A JP2018538551 A JP 2018538551A JP 2019506159 A5 JP2019506159 A5 JP 2019506159A5
- Authority
- JP
- Japan
- Prior art keywords
- aptamer
- factor
- complement factor
- aptamer according
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091023037 Aptamer Proteins 0.000 claims description 150
- 102000003706 Complement factor D Human genes 0.000 claims description 96
- 108090000059 Complement factor D Proteins 0.000 claims description 96
- 238000003556 assay Methods 0.000 claims description 28
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 27
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 27
- 239000003112 inhibitor Substances 0.000 claims description 27
- 150000003384 small molecules Chemical class 0.000 claims description 27
- 230000000694 effects Effects 0.000 claims description 23
- 108091008103 RNA aptamers Proteins 0.000 claims description 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 18
- 230000003197 catalytic effect Effects 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 18
- 206010018910 Haemolysis Diseases 0.000 claims description 14
- 230000008588 hemolysis Effects 0.000 claims description 14
- SUGXUUGGLDCZKB-UHFFFAOYSA-N 3,4-dichloroisocoumarin Chemical group C1=CC=C2C(Cl)=C(Cl)OC(=O)C2=C1 SUGXUUGGLDCZKB-UHFFFAOYSA-N 0.000 claims description 9
- 108090000371 Esterases Proteins 0.000 claims description 8
- 230000002949 hemolytic effect Effects 0.000 claims description 6
- 239000003054 catalyst Substances 0.000 claims 9
- 230000000295 complement effect Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000001908 autoinhibitory effect Effects 0.000 description 16
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022039070A JP2022078283A (ja) | 2016-01-20 | 2022-03-14 | Ｄ因子を阻害するための組成物および方法 |
| JP2023220791A JP2024029136A (ja) | 2016-01-20 | 2023-12-27 | Ｄ因子を阻害するための組成物および方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662281092P | 2016-01-20 | 2016-01-20 | |
| US62/281,092 | 2016-01-20 | ||
| US201662297095P | 2016-02-18 | 2016-02-18 | |
| US62/297,095 | 2016-02-18 | ||
| PCT/US2017/014458 WO2017127761A1 (en) | 2016-01-20 | 2017-01-20 | Compositions and methods for inhibiting factor d |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022039070A Division JP2022078283A (ja) | 2016-01-20 | 2022-03-14 | Ｄ因子を阻害するための組成物および方法 |
| JP2023220791A Division JP2024029136A (ja) | 2016-01-20 | 2023-12-27 | Ｄ因子を阻害するための組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019506159A JP2019506159A (ja) | 2019-03-07 |
| JP2019506159A5 true JP2019506159A5 (cg-RX-API-DMAC7.html) | 2020-02-27 |
Family
ID=59362699
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018538551A Pending JP2019506159A (ja) | 2016-01-20 | 2017-01-20 | Ｄ因子を阻害するための組成物および方法 |
| JP2022039070A Pending JP2022078283A (ja) | 2016-01-20 | 2022-03-14 | Ｄ因子を阻害するための組成物および方法 |
| JP2023220791A Pending JP2024029136A (ja) | 2016-01-20 | 2023-12-27 | Ｄ因子を阻害するための組成物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022039070A Pending JP2022078283A (ja) | 2016-01-20 | 2022-03-14 | Ｄ因子を阻害するための組成物および方法 |
| JP2023220791A Pending JP2024029136A (ja) | 2016-01-20 | 2023-12-27 | Ｄ因子を阻害するための組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US10174325B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3405577B8 (cg-RX-API-DMAC7.html) |
| JP (3) | JP2019506159A (cg-RX-API-DMAC7.html) |
| CN (1) | CN108934169A (cg-RX-API-DMAC7.html) |
| AU (3) | AU2017210042B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3011819A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB2553252B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017127761A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AP2016009435A0 (en) | 2014-02-25 | 2016-09-30 | Achillion Pharmaceuticals Inc | Ether compounds for treatment of complement mediated disorders |
| WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
| EP3340983B1 (en) | 2015-08-26 | 2023-10-04 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
| AU2017210042B2 (en) | 2016-01-20 | 2021-01-21 | 396419 B.C. Ltd. | Compositions and methods for inhibiting Factor D |
| WO2018136831A1 (en) * | 2017-01-20 | 2018-07-26 | Vitrisa Therapeutics, Inc. | Pseudoknot compositions and methods for inhibiting factor d |
| WO2018136827A1 (en) | 2017-01-20 | 2018-07-26 | Vitrisa Therapeutics, Inc. | Stem-loop compositions and methods for inhibiting factor d |
| MX2019010381A (es) | 2017-03-01 | 2020-01-21 | Achillion Pharmaceuticals Inc | Compuestos farmaceuticos de arilo, heteroarilo y heterociclicos para el tratamiento de trastornos medicos. |
| WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
| WO2019022986A1 (en) * | 2017-07-24 | 2019-01-31 | Vitrisa Therapeutics, Inc. | NUCLEIC ACID COMPOSITIONS AND METHODS OF INHIBITING D-FACTOR |
| WO2019028284A1 (en) | 2017-08-02 | 2019-02-07 | Achillion Pharmaceuticals, Inc. | THERAPEUTIC REGIMES FOR THE TREATMENT OF NOCTURNAL PAROXYSTIC HEMOGLOBINURIA |
| WO2019210194A1 (en) * | 2018-04-26 | 2019-10-31 | Vitrisa Therapeutics, Inc. | Pegylated compositions for ocular use, and methods thereof |
| MX2021002640A (es) | 2018-09-06 | 2021-07-16 | Achillion Pharmaceuticals Inc | Formas morficas de los inhibidores del factor d del complemento. |
| US11814391B2 (en) | 2018-09-06 | 2023-11-14 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for the treatment of medical disorders |
| MX2021003425A (es) | 2018-09-25 | 2021-07-16 | Achillion Pharmaceuticals Inc | Formas morficas de los inhibidores del factor d del complemento. |
| AU2019406830A1 (en) | 2018-12-17 | 2021-07-08 | Achillion Pharmaceuticals, Inc. | Targeted dosing for the treatment of complement mediated disorders |
| WO2020146731A1 (en) * | 2019-01-11 | 2020-07-16 | Drive Therapeutics Llc | Compositions and methods for inhibiting vascular endothelial growth factor |
| WO2020198062A1 (en) | 2019-03-22 | 2020-10-01 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement mediated disorders |
| US20220395557A1 (en) * | 2019-10-23 | 2022-12-15 | Gemini Therapeutics Sub, Inc. | Methods for treating patients having cfh mutations with recombinant cfh proteins |
| CN114686481B (zh) * | 2020-12-31 | 2023-08-15 | 北京键凯科技股份有限公司 | 一种抑制cfd表达的干扰rna及其制备方法和应用 |
| US20250129371A1 (en) * | 2023-10-11 | 2025-04-24 | Regeneron Pharmaceuticals, Inc. | Treatment Of Macular Degeneration With Complement Factor D (CFD) Inhibitors |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6140490A (en) | 1996-02-01 | 2000-10-31 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands of complement system proteins |
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| DE69128350T2 (de) | 1990-06-11 | 1998-03-26 | Nexstar Pharmaceuticals Inc | Nukleinsäureliganden |
| WO1998055471A1 (en) | 1997-06-03 | 1998-12-10 | Biocryst Pharmaceuticals, Inc. | Novel compounds useful in the complement, coagulat and kallikrein pathways and method for their preparation |
| AU756490B2 (en) | 1997-08-26 | 2003-01-16 | Abgenix, Inc. | A process for inhibiting complement activation via the alternative pathway |
| AU1252099A (en) | 1997-11-26 | 1999-06-15 | Medical Research Council | Improved selex procedure and an anti-cd4 aptamer |
| US7112327B2 (en) | 1998-02-20 | 2006-09-26 | Tanox, Inc. | Inhibition of complement activation |
| US6956107B2 (en) | 1998-02-20 | 2005-10-18 | Tanox, Inc. | Inhibitors of complement activation |
| GB9930659D0 (en) | 1999-12-24 | 2000-02-16 | Bio Discovery Ltd | Inhibitors of complement activation |
| DK1265929T3 (da) | 2000-03-23 | 2009-11-16 | Genentech Inc | Anti-C2/C2a-inhibitorer til komplement aktivering |
| EP1594541A4 (en) | 2003-02-21 | 2007-03-28 | Rikshospitalet Radiumhospitale | METHOD AND COMPOSITIONS FOR TREATING MECONIUM ASPIRATION SYNDROME |
| JP5137053B2 (ja) | 2004-02-10 | 2013-02-06 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト | 抗ｂ因子抗体もしくはその抗原結合性フラグメント、それを含む組成物、抗原結合性ポリペプチド、および治療薬 |
| US7803931B2 (en) | 2004-02-12 | 2010-09-28 | Archemix Corp. | Aptamer therapeutics useful in the treatment of complement-related disorders |
| EP1861114B1 (en) | 2005-03-11 | 2011-02-02 | Potentia Pharmaceuticals, Inc. | Compositions comprising modulators of g-protein-coupled receptor for treatment of macular degeneration |
| JP5707024B2 (ja) | 2005-05-26 | 2015-04-22 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ | 外傷性脳損傷、脊髄損傷および関連状態を治療するために補体副経路を阻害する作用剤 |
| US8168584B2 (en) * | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| MX2008004693A (es) | 2005-10-21 | 2008-09-03 | Catalyst Biosciences Inc | Proteasas modificadas que inhiben la activacion del complemento. |
| NZ567483A (en) | 2005-11-04 | 2012-04-27 | Genentech Inc | Use of complement pathway inhibitors to treat ocular diseases |
| BRPI0620249A2 (pt) | 2005-12-22 | 2011-11-08 | Alcon Res Ltd | inibidores de c3-convertase para prevenção e tratamento de degeneração macular correlacionada à idade em pacientes com riscos alternativos do fator h de complemento |
| DE602006014026D1 (de) | 2005-12-22 | 2010-06-10 | Opko Ophthalmics Llc | Zusammensetzungen und verfahren zur regulierung eines komplementsystems |
| US20070196367A1 (en) | 2006-02-22 | 2007-08-23 | Valentin Dinu | Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system |
| CN104623692A (zh) | 2006-03-08 | 2015-05-20 | 阿切埃米克斯股份有限公司 | 治疗视觉失调中使用的补体结合适体和抗-c5药物 |
| HUE026042T2 (en) | 2006-10-10 | 2016-05-30 | Regenesance B V | Complement inhibition for improved nerve regeneration |
| US8790924B2 (en) | 2006-10-19 | 2014-07-29 | Duke University | Reversible platelet inhibition |
| DK2097455T3 (en) | 2006-11-02 | 2014-12-15 | Genentech Inc | HUMANIZED ANTI-FACTOR D ANTIBODIES |
| PL2148691T3 (pl) | 2007-02-05 | 2015-12-31 | Apellis Pharmaceuticals Inc | Analogi kompstatyny do stosowania w leczeniu stanów zapalnych układu oddechowego |
| WO2009029669A1 (en) | 2007-08-27 | 2009-03-05 | Novelmed Therapeutics, Inc. | Method of inhibiting complement activation with factor bb specific antibodies |
| KR20100014486A (ko) * | 2007-04-30 | 2010-02-10 | 알콘 리서치, 리미티드 | 보체 인자 ｄ의 저해제를 사용한 연령 관련 황반변성의 치료 |
| AR066660A1 (es) * | 2007-05-23 | 2009-09-02 | Genentech Inc | Prevencion y tratamiento de condiciones del ojo asociadas con su complemento |
| US20090092980A1 (en) | 2007-07-20 | 2009-04-09 | Christoph Arenz | miRNA PROCESSING INHIBITOR EFFICACY ASSAYS AND SUBSTANCES |
| GB0718737D0 (en) | 2007-09-25 | 2007-11-07 | Glaxo Group Ltd | Antibodies |
| UY31520A1 (es) | 2007-12-11 | 2009-08-03 | Proteinas de union a antigenos | |
| US10632170B2 (en) | 2008-02-19 | 2020-04-28 | The Trustees Of The University Of Pennsylvania | Administration of compstatin to an individual for the treatment of a tumor |
| US8940299B2 (en) | 2008-02-28 | 2015-01-27 | Case Western Reserve University | Method of treating cancer |
| PL2262831T3 (pl) | 2008-03-03 | 2015-08-31 | Novelmed Therapeutics Inc | Przeciwciała przeciwko properdynie |
| US8664362B2 (en) | 2008-03-03 | 2014-03-04 | NovelMed Therapeutics | Humanized and chimeric anti-properdin antibodies |
| EP2278987A4 (en) | 2008-03-28 | 2012-08-22 | Apellis Ag | MODULATION AND REPLY / IMPROVEMENT OF THE COMPLEMENTARY SYSTEM IN THE TREATMENT OF TRAUMATISM |
| CR20170001A (es) * | 2008-04-28 | 2017-08-10 | Genentech Inc | Anticuerpos anti factor d humanizados |
| EP2159286A1 (en) | 2008-09-01 | 2010-03-03 | Consiglio Nazionale Delle Ricerche | Method for obtaining oligonucleotide aptamers and uses thereof |
| US20110160636A1 (en) | 2008-09-10 | 2011-06-30 | Rekha Bansal | Device and method for inhibiting complement activation |
| GB0904427D0 (en) * | 2009-03-13 | 2009-04-29 | Lachmann Peter | Treatment of diseases related to hyperactivity of the complement system |
| AU2010248380B2 (en) | 2009-05-15 | 2013-12-19 | Nec Solution Innovators, Ltd. | Aptamer that recognizes peptide |
| WO2011003098A1 (en) | 2009-07-02 | 2011-01-06 | Musc Foundation For Research Development | Methods of stimulating liver regeneration |
| US9278108B2 (en) | 2009-07-16 | 2016-03-08 | Nec Solution Innovators, Ltd. | HMGB1 binding nucleic acid molecule and applications thereof |
| WO2011017229A2 (en) | 2009-08-06 | 2011-02-10 | Tufts - New England Medical Center | Plasma complement components as expression markers for age-related macular degeneration and related phenotypes |
| US20110165648A1 (en) * | 2009-11-04 | 2011-07-07 | Menno Van Lookeren Campagne | Co-crystal structure of factor D and anti-factor D antibody |
| JP2013544512A (ja) | 2010-11-01 | 2013-12-19 | ジェネンテック， インコーポレイテッド | 多遺伝子スコアを用いた後期加齢性黄斑変性症への進行の予測 |
| WO2012093101A1 (en) | 2011-01-04 | 2012-07-12 | Novartis Ag | Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd) |
| BR112013033272A2 (pt) | 2011-06-22 | 2020-11-10 | Apellis Pharmaceuticals, Inc. | composição farmaceutica compreendendo um inibidor do complemento e um agente anti-th17, e usos dos mesmos |
| US10966945B2 (en) | 2011-08-01 | 2021-04-06 | Aurin Biotech Inc. | Selective inhibition of the membrane attack complex of complement by low molecular weight components of the aurin tricarboxylic synthetic complex |
| AU2012317323B2 (en) | 2011-09-28 | 2017-10-05 | Fujimoto Pharmaceutical Corporation | NGF aptamer and application thereof |
| US9316647B2 (en) | 2011-12-30 | 2016-04-19 | Somalogic, Inc. | Aptamers and diagnostic methods for detecting the EGF receptor |
| NZ712727A (en) | 2013-03-14 | 2017-05-26 | Caribou Biosciences Inc | Compositions and methods of nucleic acid-targeting nucleic acids |
| JP6463359B2 (ja) | 2013-08-12 | 2019-01-30 | ジェネンテック， インコーポレイテッド | 補体関連病態を治療するための組成物及び方法 |
| WO2015054569A1 (en) | 2013-10-10 | 2015-04-16 | Viropharma Holdings Limited | Methods of inhibiting the alternative pathway of complement immune system activation and compositions used therein |
| AP2016009435A0 (en) | 2014-02-25 | 2016-09-30 | Achillion Pharmaceuticals Inc | Ether compounds for treatment of complement mediated disorders |
| EA201692109A1 (ru) * | 2014-05-01 | 2017-03-31 | Дженентек, Инк. | Варианты антител к фактору d и их применение |
| TWI623617B (zh) | 2014-08-29 | 2018-05-11 | 國立清華大學 | 對卵巢癌具有專一性之適合體及其應用 |
| JP2018535679A (ja) | 2015-11-19 | 2018-12-06 | ベース ペア バイオテクノロジーズ，インク． | 標的分子の高感度検出のための方法及び材料 |
| AU2017210042B2 (en) | 2016-01-20 | 2021-01-21 | 396419 B.C. Ltd. | Compositions and methods for inhibiting Factor D |
| EP3405575A4 (en) | 2016-01-20 | 2019-06-26 | Vitrisa Therapeutics, Inc. | PROCESS FOR IMPROVED APTAMER SELECTION |
| EP3414330A4 (en) | 2016-02-08 | 2019-07-03 | Vitrisa Therapeutics, Inc. | COMPOSITIONS WITH IMPROVED INTRAVITREAL HALF TIME AND USES THEREOF |
| WO2018136827A1 (en) | 2017-01-20 | 2018-07-26 | Vitrisa Therapeutics, Inc. | Stem-loop compositions and methods for inhibiting factor d |
| WO2018136831A1 (en) | 2017-01-20 | 2018-07-26 | Vitrisa Therapeutics, Inc. | Pseudoknot compositions and methods for inhibiting factor d |
| WO2019022986A1 (en) | 2017-07-24 | 2019-01-31 | Vitrisa Therapeutics, Inc. | NUCLEIC ACID COMPOSITIONS AND METHODS OF INHIBITING D-FACTOR |
-
2017
- 2017-01-20 AU AU2017210042A patent/AU2017210042B2/en active Active
- 2017-01-20 JP JP2018538551A patent/JP2019506159A/ja active Pending
- 2017-01-20 EP EP17742071.8A patent/EP3405577B8/en active Active
- 2017-01-20 CA CA3011819A patent/CA3011819A1/en active Pending
- 2017-01-20 GB GB1718801.2A patent/GB2553252B/en active Active
- 2017-01-20 WO PCT/US2017/014458 patent/WO2017127761A1/en not_active Ceased
- 2017-01-20 CN CN201780018764.5A patent/CN108934169A/zh active Pending
- 2017-08-31 US US15/693,361 patent/US10174325B2/en active Active
-
2018
- 2018-09-04 US US16/121,458 patent/US20190161755A1/en not_active Abandoned
-
2020
- 2020-01-14 US US16/742,741 patent/US11274307B2/en active Active
-
2021
- 2021-04-20 AU AU2021202392A patent/AU2021202392B2/en active Active
-
2022
- 2022-03-14 JP JP2022039070A patent/JP2022078283A/ja active Pending
-
2023
- 2023-04-27 AU AU2023202548A patent/AU2023202548A1/en not_active Abandoned
- 2023-12-27 JP JP2023220791A patent/JP2024029136A/ja active Pending
-
2024
- 2024-07-05 US US18/765,089 patent/US20250197868A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019506159A5 (cg-RX-API-DMAC7.html) | ||
| JP2009531283A5 (cg-RX-API-DMAC7.html) | ||
| JP2011515073A5 (cg-RX-API-DMAC7.html) | ||
| EA200700136A1 (ru) | Анти-cd154-антитела | |
| WO2008140653A3 (en) | Humaneered anti-factor b antibody | |
| RU2015126533A (ru) | Анти-cd47 антитела и способы их применения | |
| UY28641A1 (es) | Anticuerpos | |
| BR0211953A (pt) | Inibidores de rota complementar ligando-se a cs e csa sem prevenção da formação de csb | |
| AR046682A1 (es) | Terapia de combinacion para tratamiento de desordenes neovasculares oculares | |
| NZ600348A (en) | Anti-c5a binding moieties with high blocking activity | |
| DK1819830T3 (da) | Fremgangsmåder til antistofgenerering | |
| PL1772465T3 (pl) | Syntetyczne domeny immunoglobulinowe o właściwościach wiążących modyfikowane w regionach cząsteczki różnych od regionów determinujących komplementarność | |
| HRP20090517T1 (hr) | Protutijela na interleukin-10 | |
| JP2017113019A5 (cg-RX-API-DMAC7.html) | ||
| JP2017507657A5 (cg-RX-API-DMAC7.html) | ||
| DK3085783T3 (da) | Bispecifikt antistof som substitution for funktionelle proteiner | |
| NO20081354L (no) | Dobbelt variabelt domeneimmunoglobin samt fremgangsmater derav | |
| NZ585622A (en) | Hepatitis c virus antibodies | |
| WO2009028880A3 (en) | Biomarker composition for detecting diabetic retinopathy and diagnostic kit therefor | |
| CN115666649A (zh) | 一种新型冠状病毒抗体的药物组合物及其用途 | |
| WO2004075838A3 (en) | Method and compositions for the treatment of meconium aspiration syndrome | |
| WO2013177035A3 (en) | Humaneered anti-factor b antibody | |
| EP3300739A3 (en) | Antibodies and related molecules that bind to 161p2f10b proteins | |
| ATE477274T1 (de) | Gegen clostridium difficile gerichtete antikörper | |
| WO2006059247A8 (en) | VACCINES, COMPOSITIONS AND METHODS BASED ON STAPHYLOCOCCUS AUREUS IRON-REGULATED SURFACE DETERMINANTS IsdA, IsdB, and IsdC |